Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers
Authors: Paolucci, G. (G.)
Pileri, S.A. (S.A.)
Pession, A. (A.)
Zinzani, P.L. (P.L.)
Rodriguez-Calvillo, M. (Mercedes)
Inoges, S. (Susana)
Sartini, R. (R.)
Turi, C. (C.)
Botti, S. (S.)
Maffei, R. (R.)
Tonelli, R. (R.)
Bendandi, M. (Maurizio)
Keywords: Tumor-specific
PCR
Follicular lymphoma
Consensus primers
CDR3
Issue Date: 2001
Publisher: Oxford University Press
Publisher version: http://annonc.oxfordjournals.org/content/12/10/1479.long
ISSN: 1569-8041
Citation: Bendandi M, Tonelli R, Maffei R, Botti S, Turi C, Sartini R, et al. Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann Oncol 2001 Oct;12(10):1479-1484.
Abstract
Abstract BACKGROUND: The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (VH) is the most reliable molecular fingerprint for most if not all human B cells. The nucleotide sequence encoding for any B-cell tumor-specific VH CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or bacterial cloning. PATIENTS AND METHODS: In six consecutive patients with follicular lymphoma we assessed the feasibility of a method that allows for identification of the tumor-specific VH CDR3 using consensus primers while avoiding both radioactive materials and bacterial cloning procedures. RESULTS: The tumor-specific VH CDR3 was successfully identified in all six patients in nearly half the time typically required by any other method currently utilized. The feasibility of the proposed method was not significantly affected either by the tumor-specific Ig isotype, or by the tumor infiltration in the original biopsy specimen. In the three patients for whom tumor specimen-derived hybridomas were available, the tumor-specific VH CDR3 was also found in at least 8 of 10 of them. CONCLUSIONS: The proposed method allows the ability to quickly identify the B-cell tumor-specific VH CDR3 using consensus primers while avoiding radioactive materials and bacterial cloning procedures.
Permanent link: http://hdl.handle.net/10171/19954
Appears in Collections:DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:
File:  Ann Oncol _12 2001.pdf
Description: 
Size:  1,56 MB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.